How it works:
Pomalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and anti-proliferative properties. It enhances immune activity by boosting T-cell and natural killer cell function and inhibits the formation of tumour-feeding blood vessels.
Recommended for:
Adults with relapsed/refractory multiple myeloma
Patients resistant to lenalidomide and bortezomib
Individuals needing third-line therapy support
Treatment under the supervision of a qualified oncologist
Relapsed or refractory multiple myeloma in adults who have received at least two prior therapies including lenalidomide and bortezomib
The tablets are taken orally once daily on days 1–21 of each 28-day cycle, followed by 7 days off. Usually administered with dexamethasone. Dosage should be prescribed individually by the treating physician depending on clinical response and tolerance.
Hypersensitivity to pomalidomide or excipients
Pregnancy or breastfeeding
Patients under 18 years of age
Severe hepatic or renal impairment
Neutropenia, thrombocytopenia, anaemia
Fatigue, weakness
Constipation, diarrhoea, nausea
Rash, skin reactions
Respiratory infections, pneumonia
Thromboembolic events
Elevated liver enzymes
